Genmab A/S (CPH:GMAB)
Denmark · Delayed Price · Currency is DKK | Market Cap | 157.99B +33.7% |
| Revenue (ttm) | 27.03B +22.3% |
| Net Income | 5.16B -37.9% |
| EPS | 82.78 -36.8% |
| Shares Out | 59.75M |
| PE Ratio | 31.94 |
| Forward PE | 31.46 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 114,865 |
| Open | 2,648.00 |
| Previous Close | 2,654.00 |
| Day's Range | 2,621.00 - 2,685.00 |
| 52-Week Range | 1,512.00 - 2,680.00 |
| Beta | 0.65 |
| Analysts | Strong Buy |
| Price Target | 2,775.93 (+4.99%) |
| Earnings Date | Nov 5, 2026 |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell n... [Read more]
Financial Performance
In 2025, Genmab's revenue was $3.72 billion, an increase of 19.19% compared to the previous year's $3.12 billion. Earnings were $963.00 million, a decrease of -15.00%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for GMAB stock is "Strong Buy." The 12-month stock price target is kr 2,776, which is an increase of 4.99% from the latest price.
News
Genmab Press release: Study result
Genmab issued a press release on October 28, 2026, disclosing material business information to investors.
Genmab announces updated analyses from Phase 2 trial of petosemtamab
Genmab (GMAB) announced updated follow-up analyses from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor, EGFR, and l...
Incyte, Genmab announce clinical trial collaboration to evaluate INCB161734
Incyte (INCY) and Genmab A/S (GMAB) announced a clinical trial collaboration to evaluate INCB161734, Incyte’s investigational, potent and selective KRAS G12D inhibitor, in combination with petosemtama...
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
Media Release COPENHAGEN, Denmark; October 25, 2026 Petosemtamab demonstrates encouraging objective response rates (ORRs), with promising depth and durability of response, in first- and second-line me...
Genmab, Incyte Partner On Trial Of Petosemtamab Combination In KRAS G12D-Mutated Colorectal Cancer
(RTTNews) - Genmab A/S (GMAB) and Incyte (INCY) have entered into a clinical trial collaboration to evaluate a novel combination therapy for patients with metastatic colorectal cancer (mCRC) harboring...
Genmab A/S: Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) Genmab A/S (Nasdaq: GMAB) and Incyt...
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
COPENHAGEN, Denmark & WILMINGTON, Del.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab's investiga...
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Media Release COPENHAGEN, Denmark and WILMINGTON, Del.; October 24, 2026 Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated me...
Corcept Therapeutics (CORT) Shares Drop 20% on Genmab's Phase 3 Success in Ovarian Cancer
Corcept Therapeutics (CORT) Shares Drop 20% on Genmab's Phase 3 Success in Ovarian Cancer
Genmab (GMAB) Reports Positive Phase 3 RAINFOL-02 Trial Results for Ovarian Cancer Therapy
Genmab (GMAB) Reports Positive Phase 3 RAINFOL-02 Trial Results for Ovarian Cancer Therapy
Genmab A/S Announces Positive Topline Results from Phase 3 RAINFOL-02 Trial
Genmab A/S announced positive topline results from the global Phase 3 RAINFOL™-02 trial of rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOP...
Genmab says Phase 3 ovarian cancer trial met primary endpoint
11:57 EDT Genmab (GMAB) says Phase 3 ovarian cancer trial met primary endpoint
Genmab jumps 4$ to $41.61 after ovarian cancer trial data
11:58 EDT Genmab (GMAB) jumps 4$ to $41.61 after ovarian cancer trial data
Genmab says Phase 3 Rainfol-02 trial met primary endpoint of PFS
Genmab (GMAB) announced positive topline results from the global Phase 3 RAINFOL-02 trial of rinatabart sesutecan, an investigational folate receptor alpha-targeted, topoisomerase I-inhibitor antibody...
Genmab A/S: Genmab Announces Rinatabart Sesutecan (Rina-S) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Phase 3 RAINFOL-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart sesutecan (Rina-S) compared to investig...
Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today positive topline results from the global Phase 3 RAINFOL™-02 trial of rinatabart sesutecan (Rina-S®), an investigational...
Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Company Announcement COPENHAGEN, Denmark; October 23, 2026 Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS)...
Genmab price target raised to $42 from $35 at Morgan Stanley
Morgan Stanley analyst Judah Fommer raised the firm’s price target on Genmab (GMAB) to $42 from $35 and keeps an Equal Weight rating on the shares.
Genmab Reports $4.24 Billion In Third-Quarter DARZELEX Sales, Up Year Over Year
(RTTNews) - Genmab (GMAB) announced that worldwide net sales of DARZALEX (daratumumab), as reported by partner Johnson & Johnson (JNJ), totaled $4.24 billion during the third quarter of 2026, up from ...
Genmab reports Q3 net sales of Darzalex $4.24B
Genmab (GMAB) announced that worldwide net trade sales of Darzalex – daratumumab -, including sales of the subcutaneous product sold under the tradename Darzalex Faspro in the U.S., as reported…
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026
Company Announcement Net sales of DARZALEX ® in the third quarter of 2026 totaled USD 4,239 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen B...
Genmab (CPH:GEN) -- Pipeline Progress and Market Resilience | Baird Funds Q3 2026
Genmab (CPH:GEN) -- Pipeline Progress and Market Resilience | Baird Funds Q3 2026
Genmab To Issue Restricted Stock Units To Board Members As Renumeration
(RTTNews) - Genmab A/S (GMAB), a biotechnology company, on Wednesday reported the results of an Extraordinary General Meeting to determine a share-based renumeration for the company's Board of Directo...
Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members
Company Announcement COPENHAGEN, Denmark; October 7, 2026 – Genmab A/S (Nasdaq: GMAB) Today, Genmab A/S held an Extraordinary General Meeting.At the Extraordinary General Meeting the proposal from ...
Genmab price target raised to $45 from $40 at Truist
Truist raised the firm’s price target on Genmab (GMAB) to $45 from $40 and keeps a Buy rating on the shares as part of a broader research note previewing Q3…